Literature DB >> 7488392

Regulation of cellular retinoic acid binding protein expression in rhino mouse skin by all-trans-retinoic acid.

G J Gendimenico1, J P Mallon, M A Cromie, J A Mezick, A Aström, J T Elder.   

Abstract

Cellular retinoic acid binding proteins (CRABP) are cytoplasmic proteins that bind all-trans-retinoic acid (RA) and other retinoids. The purpose of these studies was to determine the effects of topically applied RA on CRABP expression in rhino mouse skin. CRABP-II mRNA was significantly induced (3- to 4.5-fold) by a single dose of RA at 6 and 16 h after RA treatment, with a return to control levels at 48 h. CRABP-II message was not significantly elevated by 3 or 4 consecutive days of RA treatment, when assessed 24 h after the last treatment. CRABP-I mRNA was undetectable in control and RA-treated skin. We used radiolabelled RA binding combined with non-denaturing PAGE blot autoradiography to distinguish the CRABP subtypes. By this protein assay method, increases in CRABP-II were detected 24 and 48 h after a single application of RA, as well as after 3 and 4 days of RA treatment. RA treatment did not alter CRABP-I expression relative to the vehicle control. These results demonstrate that in mouse skin CRABP-II, but not CRAB-I, is inducible by RA, and is similar to how RA regulates CRABP in human skin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488392     DOI: 10.1159/000211342

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  2 in total

1.  Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

Authors:  S W Stoll; S Kansra; S Peshick; D W Fry; W R Leopold; J F Wiesen; M Sibilia; T Zhang; Z Werb; R Derynck; E F Wagner; J T Elder
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

2.  Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis.

Authors:  Po-Lin So; Michele A Fujimoto; Ervin H Epstein
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.